A recent analysis suggests that President Donald Trump’s initiatives aimed at reducing drug prices may have limited impact on the U.S. market and could inadvertently restrict access to certain medicines in Europe. The assessment was made by Lars Rebien Sørensen, former CEO of pharmaceutical company Novo Nordisk, who expressed concern that policy measures targeting U.S. drug costs might lead to unintended regional consequences.
Sørensen indicated that efforts to lower medication prices in the United States could result in manufacturers reducing their global supply or limiting availability outside the U.S., particularly in Europe. He emphasized that such changes could deprive European patients of access to certain innovative medicines, rather than significantly lowering costs domestically.
The comments highlight the complex dynamics of pharmaceutical markets, where policy changes in one region can ripple across global supply chains. Critics of the Trump administration’s approach argue that aggressive measures to contain drug prices risk stifling innovation and reducing supply, which might impact patients internationally.
While the federal government has sought to implement measures to curb high drug prices, healthcare stakeholders remain divided on the potential consequences of these policies. Experts continue to call for balanced solutions that address affordability concerns without compromising the availability of vital medications across different markets.